Zobrazeno 1 - 10
of 61
pro vyhledávání: '"Samuel Rosner"'
Autor:
Stephanie L. Alden, Harmeet Dhani, Charuta C. Palsuledesai, Shifra Krinshpun, Adham Jurdi, Eric Christenson, Ilene Browner, Samuel Rosner
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Circulating tumor DNA (ctDNA) level monitoring after surgery for colon cancer has been studied in stage II and III colon cancer to risk-stratify patients for adjuvant therapy. However, there is less data regarding the role of this diagnostic tool in
Externí odkaz:
https://doaj.org/article/aa860f81feae440ba42dcd6f94f0fd24
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100384- (2022)
Introduction: Increased efforts to optimize outcomes for early stage NSCLC through the investigation of novel perioperative treatment strategies are ongoing. An emerging question is the role of pathologic response and its association with long-term c
Externí odkaz:
https://doaj.org/article/30ccbb8e17bb45bda4bf13344b1ddf82
Autor:
Jiajia Zhang, Julie R Brahmer, Patrick M Forde, Tanguy Seiwert, Valsamo Anagnostou, Samuel Rosner, Victor E Velculescu, James R White, Joshua E Reuss, Gavin Pereira, Vincent Lam, Christine Hann, Michael Hwang, Kristen Marrone, Kellie N Smith, Joseph C Murray, Jamie E Chaft, Lavanya Sivapalan, Jenna Vanliere Canzoniero, Guangfan Zhang, Zineb Belcaid, Christopher Cherry, Archana Balan, Alexandria Curry, Noushin Niknafs, Qing Kay Li, Benjamin P Levy
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 10, Iss 6 (2022)
Externí odkaz:
https://doaj.org/article/da2666dd4bbf43a0ba1fac37b8c8e007
Publikováno v:
Forests, Vol 13, Iss 11, p 1760 (2022)
The beaver (Castor canadensis Khul) is a key species that is known to shape the composition of riparian forests. Ash trees (Fraxinus spp.) can be abundant in these forests. However, invasion by the emerald ash borer (Agrilus planipennis Fairmaire) in
Externí odkaz:
https://doaj.org/article/e03cb8768f7e422984d60ca3ce3feb18
Autor:
Jaclyn LoPiccolo, Megan D. Schollenberger, Sumia Dakhil, Samuel Rosner, Osama Ali, William H. Sharfman, Ann W. Silk, Shailender Bhatia, Evan J. Lipson
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-5 (2019)
Abstract Merkel cell carcinoma (MCC) is a rare but clinically aggressive cancer with a high mortality rate. In recent years, antibodies blocking the interactions among PD-1 and its ligands have generated durable tumor regressions in patients with adv
Externí odkaz:
https://doaj.org/article/7b45f8f72c13410fbc81486bdc94fbae
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)
Immune checkpoint inhibitors (ICIs) are associated with a range of organ-specific toxicities known as immune-related adverse events (irAEs). Immune-mediated ototoxicity from ICIs is poorly described. Herein, we describe the clinical presentation, dia
Externí odkaz:
https://doaj.org/article/296c4eaaf23a4f65aba8d6258527ac56
Autor:
Samuel Rosner, Erica Kwong, Alexander N. Shoushtari, Claire F. Friedman, Allison S. Betof, Mary Sue Brady, Daniel G. Coit, Margaret K. Callahan, Jedd D. Wolchok, Paul B. Chapman, Katherine S. Panageas, Michael A. Postow
Publikováno v:
Cancer Medicine, Vol 7, Iss 3, Pp 690-697 (2018)
Abstract Both the combination of nivolumab + ipilimumab and single‐agent anti‐PD‐1 immunotherapy have demonstrated survival benefit for patients with advanced melanoma. As the combination has a high rate of serious side effects, further analyse
Externí odkaz:
https://doaj.org/article/40cdf6b335224da48d2ae318d785a6cf
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 5, Iss 1, Pp 1-5 (2017)
Abstract Background Myelophthisis due to melanoma is a rare phenomenon. Treatment strategies for patients with this serious complication of malignancy have not been well documented, and none have previously reported efficacy of immune checkpoint inhi
Externí odkaz:
https://doaj.org/article/23698fb19141460fbd35a3b54bf31dc9
Autor:
Samuel Rosner, Joshua E. Reuss, Marianna Zahurak, Jiajia Zhang, Zhen Zeng, Janis Taube, Valsamo Anagnostou, Kellie N. Smith, Joanne Riemer, Peter B. Illei, Stephen R. Broderick, David R. Jones, Suzanne L. Topalian, Drew M. Pardoll, Julie R. Brahmer, Jamie E. Chaft, Patrick M. Forde
Publikováno v:
Clinical Cancer Research. 29:705-710
Purpose:Neoadjuvant anti–PD-1 therapy has shown promise for resectable non–small cell lung cancer (NSCLC). We reported the first phase I/II trial of neoadjuvant nivolumab in resectable NSCLC, finding it to be safe and feasible with encouraging ma
Publikováno v:
Future Oncology.
Adagrasib is a recently US FDA-approved novel KRASG12C targeted therapy with clinical efficacy in patients with advanced, pretreated KRASG12C-mutated non-small-cell lung cancer. KRYSTAL-I reported an objective response rate of 42.9% with median durat